Structural-Functional Analysis of 2,1,3-Benzoxadiazoles and Their N-oxides As HIV-1 Integrase Inhibitors
- Authors: Korolev S.P.1,2, Kondrashina O.V.1,2, Druzhilovsky D.S.3, Starosotnikov A.M.4, Dutov M.D.4, Bastrakov M.A.4, Dalinger I.L.4, Filimonov D.A.3, Shevelev S.A.4, Poroikov V.V.3, Agapkina Y.Y.1,2, Gottikh M.B.1,2
-
Affiliations:
- Lomonosov Moscow State University
- Belozersky Research Institute of Physicochemical Biology, Lomonosov Moscow State University
- Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
- Zelinsky Institute of Organic Chemistry, Russian Academy of Science
- Issue: Vol 5, No 1 (2013)
- Pages: 63-72
- Section: Research Articles
- Submitted: 17.01.2020
- Published: 15.03.2013
- URL: https://actanaturae.ru/2075-8251/article/view/10605
- DOI: https://doi.org/10.32607/20758251-2013-5-1-63-72
- ID: 10605
Cite item
Abstract
Human immunodeficiency virus type 1 integrase is one of the most attractive targets for the development of anti-HIV-1 inhibitors. The capacity of a series of 2,1,3-benzoxadiazoles (benzofurazans) and their N-oxides (benzofuroxans) selected using the PASS software to inhibit the catalytic activity of HIV-1 integrase was studied in the present work. Only the nitro-derivatives of these compounds were found to display inhibitory activity. The study of the mechanism of inhibition by nitro-benzofurazans/benzofuroxans showed that they impede the substrate DNA binding at the integrase active site. These inhibitors were also active against integrase mutants resistant to raltegravir, which is the first HIV-1 integrase inhibitor approved for clinical use. The comparison of computer-aided estimations of the pharmacodynamic and pharmacokinetic properties of the compounds studied and raltegravir led us to conclude that these compounds show promise and need to be further studied as potential HIV-1 integrase inhibitors.
Keywords
About the authors
S. P. Korolev
Lomonosov Moscow State University; Belozersky Research Institute of Physicochemical Biology, Lomonosov Moscow State University
Author for correspondence.
Email: spkorolev@mail.ru
Russian Federation
O. V. Kondrashina
Lomonosov Moscow State University; Belozersky Research Institute of Physicochemical Biology, Lomonosov Moscow State University
Email: spkorolev@mail.ru
Russian Federation
D. S. Druzhilovsky
Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: spkorolev@mail.ru
Russian Federation
A. M. Starosotnikov
Zelinsky Institute of Organic Chemistry, Russian Academy of Science
Email: spkorolev@mail.ru
Russian Federation
M. D. Dutov
Zelinsky Institute of Organic Chemistry, Russian Academy of Science
Email: spkorolev@mail.ru
Russian Federation
M. A. Bastrakov
Zelinsky Institute of Organic Chemistry, Russian Academy of Science
Email: spkorolev@mail.ru
Russian Federation
I. L. Dalinger
Zelinsky Institute of Organic Chemistry, Russian Academy of Science
Email: spkorolev@mail.ru
Russian Federation
D. A. Filimonov
Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: spkorolev@mail.ru
Russian Federation
S. A. Shevelev
Zelinsky Institute of Organic Chemistry, Russian Academy of Science
Email: spkorolev@mail.ru
Russian Federation
V. V. Poroikov
Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences
Email: spkorolev@mail.ru
Russian Federation
Y. Y. Agapkina
Lomonosov Moscow State University; Belozersky Research Institute of Physicochemical Biology, Lomonosov Moscow State University
Email: spkorolev@mail.ru
Russian Federation
M. B. Gottikh
Lomonosov Moscow State University; Belozersky Research Institute of Physicochemical Biology, Lomonosov Moscow State University
Email: spkorolev@mail.ru
Russian Federation
References
- Cara A., Guarnaccia F., Reitz M.S. Jr., Gallo R.C., Lori F. // Virology. 1995. V. 208. P. 242-248.
- Marcelin A.G., Ceccherini-Silberstein F., Perno C.F., Calvez V. // Curr. Opin. HIV AIDS. 2009. V. 4. P. 531-537.
- FDA approves raltegravir tablets. // AIDS Patient Care STDS. 2007. V. 21. № 11. P. 889.
- Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Kumar P.N., Eron J.E., et al. // N. Engl. J. Med. 2008. V. 359. № 4. P. 355-365.
- Korolev S.P., Agapkina Y.Y., Gottikh M.B. // Acta Naturae. 2011. V. 3. № 3. P. 12-28.
- Kobayashi M., Nakahara K., Seki T., Miki S., Kawauchi S., Suyama A., Wakasa-Morimoto C., Kodama M., Endoh T., Oosugi E., et al. // Antiviral Res. 2008. V. 80. № 2. P. 213-222.
- Keseru G.M., Makara G.M. // Nature Reviews Drug Discovery. 2009. V. 8. P. 203-212.
- Johnson B.C., Metifiot M., Pommier Y., Highes S.H. Antimicrob. Agents Chemother. 2012. V. 56. P. 411-419.
- Ma K., Wang P., Fu W., Wan X., Zhou L., Chu Y., Ye D. Bioorg. Med. Chem. Lett. 2011. V. 21. № 22. P. 6724-6727.
- Ko G.M., Reddy A.S., Garg R., Kumar S., Hadaegh A.R. // Curr. Comput. Aided Drug Des. 2012. V. 8. № 4. P. 255-270.
- Filimonov D.A., Poroikov V.V. Probabilistic approach in activity prediction. In: Chemoinformatics Approaches to Virtual Screening. Eds. Alexandre Varnek and Alexander Tropsha. Cambridge (UK): RSC Publishing. 2008. P. 182-216.
- Filimonov D.A., Poroikov V.V. // Rus. Khim. Zhurn. 2006. V. 50. № 2. P. 66-75.
- Akimov D.V., Filimonov D.A., Prikazchikova T.A., Gottikh M.B., Poroikov V.V. // Biomed. Khim. 2005. V. 51. № 3. P. 335-340.
- Druzhilovsky D.S., Filimonov D.A., Liao C., Peach M., Nicklaus M., Poroikov V.V. Biochemistry (Moscow) Supplemental Series B. Biomedical Chemistry. 2010. V. 4. №1. P. 59-67.
- Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., et al. // J. Med. Chem. 2008. V. 51. № 18. P. 5843-5855.
- http://www.schrodinger.com/products/14/17/
- Handzlik J., Bajda M., Zygmunt M., Maciąg D., Dybała M., Bednarski M., Filipek B., Malawska B., Kieć-Kononowicz K. // Bioorg. Med. Chem. 2012. V. 20. № 7. P. 2290-2303.
- Shukla S., Kumar P., Das N., Moorthy N.S., Shrivastava S.K., Trivedi P., Srivastava R.S. // Med Chem. 2012. V. 8. № 5. 834-845.
- Ghose A.K., Herbertz T., Hudkins R.L., Dorsey B.D., Mallamo J.P. // ACS Chem. Neurosci. 2012. V. 3. № 1. 50-68.
- Ghosh P.B., Whitehouse M.W. // J. Med. Chem. 1968. V. 11. P. 305-311.
- Ghosh P.B. // J. Chem. Soc. B. 1968. P. 334-338.
- Terrier F., Croisat D., Chatrousse A.-P., Pouet M.-J., Halle J.-C., Jacob G. // J. Org. Chem. 1992. V. 57. P. 3684-3689.
- Zatsepin T.S., Kachlova A.V., Romanova E.A., Stetsenko D.A., Gait M.J., Oretskaya T.S. Russian J. Bioorg. Chem. 2001. V. 27. №1. P. 39-44.
- Leh H., Brodin P., Bischerour J., Deprez E., Tauc P., Brochon J.-C., LeCam E., Coulaud D., Auclair C., Mouscadet J.-F. // Biochemistry. 2000. V. 39. P. 9285-9294.
- Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., Tchertanov L., Peytavin G., Reynes J., Mouscadet J-F., et al. // Antimicrob. Agents. Chemother. 2008. V. 52. № 4. P. 1351-1358.
- FDA approves new 4-drug once-a-day HIV treatment // AIDS Policy Law. 2012. V. 27. № 11: 1.
- Delelis, O., Malet, I., Na, L., Tchertanov, L., Calvez, V., Marcelin, A.G., Subra, F., Deprez, E., Mouscadet, J.-F. // Nucleic Acids Res. 2009. V. 37. P. 1193-1201.
- Hare S., Vos A.M., Clayton R.F., Thuring J.W., Cummings M.D., Cherepanov P. // Proc. Natl. Acad. Sci. USA. 2010. V. 107. P. 20057-20062.
- Quashie P.K., Sloan R.D., Wainberg M.A. // BMC Med. 2012. V. 10:34
- Puras Lutzke R.A., Vink C., Plasterk R.H. // Nucleic Acids Res. 1994. V. 22. № 20. P. 4125-4131.
- Smolov M., Gottikh M., Tashlitskii V., Korolev S., Demidyuk I., Brochon J-C., Mouscadet J.-F., Deprez E. // FEBS J. 2006. V. 273. P. 1137-1151.
- Michel F., Crucifix C., Granger F., Eiler S., Mouscadet J.-F., Korolev S., Agapkina J., Ziganshin R., Gottikh M., Nazabal A., et al. // EMBO J. 2009. V. 28. P. 980-991.
- Krishnan L., Li X., Naraharisetty H.L., Hare S., Cherepanov P., Engelman A. // Proc. Natl. Acad. Sci. U S A. 2010. V. 107. № 36. P. 15910-15915.
- Johnson A.A., Marchand C., Patil S.S., Costi R., Di Santo R., Burke T.R.-Jr., Pommier Y. // Mol. Pharmacol. 2007. V. 71. № 3. P. 893-901.
- Korolev S.P., Tashlitskii V.N., Smolov M.A., Gromyko A.V., Zhuze A.L., Agapkina Yu.Yu., Gottikh M.B. HIV-1 integrase inhibition by dimeric bisbenzimidazoles with different spacers. // Russian J. Mol. Biol. 2010. V. 44. №4. P. 718-727.
- Neamati N., Lin Z., Karki R.G., Orr A., Cowansage K., Strumberg D., Pais G.C., Voigt J.H., Nicklaus M.C., Winslow H.E., et al. // J. Med. Chem. 2002. V. 45. №. 26. P. 5661-5670.
- http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf
- http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000860/WC500037408.pdf